Tema ETFs LLC Acquires Shares of 29,519 Tyra Biosciences, Inc. $TYRA

Tema ETFs LLC bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 29,519 shares of the company’s stock, valued at approximately $943,000.

Other institutional investors have also recently made changes to their positions in the company. Millennium Management LLC boosted its stake in shares of Tyra Biosciences by 28.2% during the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after purchasing an additional 89,024 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after buying an additional 13,896 shares during the period. Woodline Partners LP bought a new position in shares of Tyra Biosciences during the first quarter valued at approximately $931,000. Jane Street Group LLC purchased a new stake in shares of Tyra Biosciences in the first quarter worth approximately $324,000. Finally, Geode Capital Management LLC lifted its stake in shares of Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after acquiring an additional 50,836 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several research analyst reports. Bank of America upped their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a research note on Wednesday, August 5th. JonesTrading assumed coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price objective for the company. Wolfe Research began coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $46.90.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $25.02 on Friday. Tyra Biosciences, Inc. has a 1 year low of $9.96 and a 1 year high of $40.65. The firm’s 50-day moving average is $29.78 and its two-hundred day moving average is $32.56. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -10.43 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, equities analysts expect that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current year.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.